Table 2.
Comparison of baseline data from liver cancer patients with different survival times after liver transplantation
| Group | Number of cases | Age | Liver disease duration | Gender [case (%)] | Primary disease [case (%)] | ||||
|---|---|---|---|---|---|---|---|---|---|
| (year, x ± s) | M (year, P25, P75) | Male | Female | Hepatitis B | Hepatitis C | Hepatitis B + hepatitis C | Others | ||
| < 10 years group | 81 | 49 ± 10 | 11 (5, 20) | 73 (90.1) | 8 (9.9) | 70 (86.4) | 1 (1.2) | 2 (2.5) | 8 (9.9) |
| ≥ 10 years group | 53 | 52 ± 9 | 16 (10, 20) | 47 (88.7) | 6 (11.3) | 46 (86.8) | 3 (5.66) | 1 (1.89) | 3 (5.66) |
| Test value | 1.907a | 1.691b | 0.071c | 2.852c | |||||
| P value | 0.029 | 0.091 | 0.790 | 0.415 | |||||
| Group | Number of cases | TACE history | Anti-virus history | Smoking history | Drinking history | AFP ≥ 400 µg/L | Child-Pugh stage [case (%)] | ||
|---|---|---|---|---|---|---|---|---|---|
| Case (%) | A | B | C | ||||||
| < 10 years group | 81 | 15 (18.5) | 16 (19.8) | 27 (33.3) | 26 (32.1) | 41 (50.6) | 28 (34.6) | 34 (42.0) | 19 (23.5) |
| ≥ 10 years group | 53 | 10 (18.9) | 5 (9.4) | 17 (32.1) | 20 (37.7) | 13 (24.5) | 22 (41.5) | 20 (37.7) | 11 (20.8) |
| Test value | 0.003c | 2.733c | 0.023c | 0.450c | 9.357c | 0.658c | |||
| P value | 0.960 | 0.098 | 0.879 | 0.503 | 0.002 | 0.720 | |||
TACE transcatheter arterial chemoembolization, AFP alpha-fetoprotein
a t value
b Z value
c χ 2 value